Because sarcomatoid carcinoma is associated with high PD-L1 expression in many cancer types [4–10], sarcomatoid UC may be a good candidate for immunotherapy targeting the PD-1/PD-L1 axis. The gene discussed is CD274; the disease is sarcomatoid carcinoma.